In focus · trending topic

IMRN

20 stories · following the connections

Immuron Limited Issues Correction to Misleading Halt Announcement Headline

By Nasdaq OMXMar 7, 2018, 10:06 PM UTC

Travelan® Revenue Grows Significantly in US and Australia

By Nasdaq OMXFeb 16, 2018, 2:30 PM UTC

Immuron Enrols First Patients in Clinical Study of IMM-529 for Treatment of Clostridium Difficile Infection (CDI)

By Nasdaq OMXJan 31, 2018, 2:30 PM UTC

US Defense Reports Broad Travelan® Reactivity to 180 Pathogenic Bacteria Including Camylobacter and Shigella

By Nasdaq OMXJan 29, 2018, 2:20 PM UTC

Immuron to Receive $2.16M R&D Tax Concession Refund

By Nasdaq OMXJan 24, 2018, 2:30 PM UTC

CEO to Present on US Investor TV Show and at Biotech Conference

By Nasdaq OMXJan 10, 2018, 2:04 PM UTC

Immuron to Present at RedChip’s Global Online Growth Conference

By Nasdaq OMXDec 6, 2017, 2:04 PM UTC

Van Leeuwenhoeck Institute Updates Immuron Research Coverage

By Nasdaq OMXNov 22, 2017, 2:00 PM UTC